These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 12683719)

  • 21. Targeting the tumor stroma in cancer therapy.
    Anton K; Glod J
    Curr Pharm Biotechnol; 2009 Feb; 10(2):185-91. PubMed ID: 19199950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathophysiology of tumor neovascularization.
    Furuya M; Nishiyama M; Kasuya Y; Kimura S; Ishikura H
    Vasc Health Risk Manag; 2005; 1(4):277-90. PubMed ID: 17315600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.
    Horsman MR; Siemann DW
    Cancer Res; 2006 Dec; 66(24):11520-39. PubMed ID: 17178843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
    Mancuso MR; Davis R; Norberg SM; O'Brien S; Sennino B; Nakahara T; Yao VJ; Inai T; Brooks P; Freimark B; Shalinsky DR; Hu-Lowe DD; McDonald DM
    J Clin Invest; 2006 Oct; 116(10):2610-21. PubMed ID: 17016557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential future targets for treating ocular neovascularization.
    Barouch FC; Miller JW
    Ophthalmol Clin North Am; 2006 Sep; 19(3):401-9. PubMed ID: 16935215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Manipulating Angiogenesis by Targeting Endothelial Metabolism: Hitting the Engine Rather than the Drivers-A New Perspective?
    Treps L; Conradi LC; Harjes U; Carmeliet P
    Pharmacol Rev; 2016 Jul; 68(3):872-87. PubMed ID: 27363442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dormant tumors and organs resistant to metastasis after gene transfer: dream and reality of anti-angiogenic gene therapy].
    Li H; Dkhissi F; Grenet C; Soria C; Lu H
    Therapie; 2001; 56(5):501-10. PubMed ID: 11806286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiangiogenic effects of marine sponge derived compounds on cancer.
    Senthilkumar K; Venkatesan J; Manivasagan P; Kim SK
    Environ Toxicol Pharmacol; 2013 Nov; 36(3):1097-108. PubMed ID: 24148290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal model for tumor angiogenesis.
    Kevrekidis PG; Whitaker N; Good DJ; Herring GJ
    Phys Rev E Stat Nonlin Soft Matter Phys; 2006 Jun; 73(6 Pt 1):061926. PubMed ID: 16906883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumors' do-it-yourself blood vessels.
    Leslie M
    Science; 2016 Jun; 352(6292):1381-3. PubMed ID: 27313019
    [No Abstract]   [Full Text] [Related]  

  • 31. Therapeutic inhibition of angiogenesis.
    Zhang HT; Bicknell R
    Mol Biotechnol; 2003 Oct; 25(2):185-200. PubMed ID: 14526126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The new cancer blockers.
    Johns Hopkins Med Lett Health After 50; 2004 Oct; 17(8):1-2, 7. PubMed ID: 15602777
    [No Abstract]   [Full Text] [Related]  

  • 33. Angiogenesis, a target for tumor therapy.
    Griffioen AW; Barendsz-Janson AF; Mayo KH; Hillen HF
    J Lab Clin Med; 1998 Nov; 132(5):363-8. PubMed ID: 9823929
    [No Abstract]   [Full Text] [Related]  

  • 34. [Advances in the study of tumor angiogenesis and anti-angiogenic Chinese herbal drugs].
    Tao X; Tang D
    Zhong Yao Cai; 2003 May; 26(5):379-81. PubMed ID: 14632026
    [No Abstract]   [Full Text] [Related]  

  • 35. Endothelial Side Population Cells Contribute to Tumor Angiogenesis and Antiangiogenic Drug Resistance.
    Naito H; Wakabayashi T; Kidoya H; Muramatsu F; Takara K; Eino D; Yamane K; Iba T; Takakura N
    Cancer Res; 2016 Jun; 76(11):3200-10. PubMed ID: 27197162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic.
    Ye W
    Dev Cell; 2016 Apr; 37(2):114-25. PubMed ID: 27093081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Significance of vascular endothelial growth factor--VEGF--in tumor angiogenesis. Therapeutic possibilities in solid tumors].
    Werther K; Nielsen HJ
    Ugeskr Laeger; 2000 Sep; 162(37):4916-20. PubMed ID: 11002739
    [No Abstract]   [Full Text] [Related]  

  • 38. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.
    van Heeckeren WJ; Sanborn SL; Narayan A; Cooney MM; McCrae KR; Schmaier AH; Remick SC
    Curr Opin Hematol; 2007 Sep; 14(5):468-80. PubMed ID: 17934353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor angiogenesis and therapy.
    Cao Y
    Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S340-3. PubMed ID: 16507405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The circulating endothelial cell in cancer: towards marker and target identification.
    Martin-Padura I; Bertolini F
    Curr Pharm Des; 2008; 14(36):3780-9. PubMed ID: 19128231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.